Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,626 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06197425RecruitingPhase 3
Extra chemotherapy after surgery for colorectal cancer with positive ctDNA
This trial tests whether giving more chemotherapy can help people who still have cancer DNA in their blood after surgery and standard chemotherapy for colorectal cancer. The goal is to prevent the cancer from coming back.
DijonAges 18–80 - NCT06156527RecruitingPhase 2
Lazertinib alone vs lazertinib plus Avastin for EGFR+ lung cancer in smokers
This trial tests if adding bevacizumab (Avastin) to lazertinib works better than lazertinib alone for advanced non-small cell lung cancer with an EGFR mutation. It is for people who have smoked at least 100 cigarettes in their lifetime.
Suwon, Gyeonggi-doAges 19 years+ - NCT07007910RecruitingPhase 1
Study of HSK46575 for advanced prostate cancer
This trial tests a new drug, HSK46575, for men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy and chemotherapy. The goal is to see if it can help slow the cancer's growth.
Chengdu, SichuanAges 18 years+ - NCT07012954RecruitingPhase 1/Phase 2
ctDNA-guided treatment for RAS/BRAF wild-type colorectal cancer
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
Guangzhou, GuangdongAges 18–75 - NCT06100705RecruitingPhase 2
Combination therapy for men with advanced prostate cancer
This trial tests combining an immunotherapy (Sipuleucel-T) with high-dose testosterone to see if it works better for men with castration-resistant prostate cancer that has spread.
New Haven, ConnecticutAges 18 years+ - NCT05345847Recruiting
Steroid-sparing treatment for immune hepatitis during cancer immunotherapy
This trial studies a way to treat inflammation of the liver (hepatitis) caused by immune cancer medicines (anti-PD-1/PD-L1, sometimes with anti-CTLA-4) without relying on high-dose steroids. It may help reduce steroid side effects while keeping liver inflammation under control.
Calgary, AlbertaAges 18 years+ - NCT07352930Recruiting
Fluorescence-guided system for breast cancer surgery margins
This trial tests a new imaging system that helps surgeons see if cancer cells remain after breast-conserving surgery. It may reduce the need for a second surgery by giving real-time feedback on the removed tissue.
Guangzhou, GuangdongAges 18 years+ - NCT07193862RecruitingEarly Phase 1
Testing a tiny device to find best treatments for liver tumors
This study tests a tiny device that is placed in your liver tumor during surgery. It checks how well different chemotherapy drugs work on your specific cancer, which may help your doctor choose the best treatment for you.
Lake Success, New YorkAges 18 years+ - NCT07670949Recruiting
68Ga-EV203 imaging for blood cancers
This trial uses a special imaging agent called 68Ga-EV203 to see where certain blood cancers (multiple myeloma, non-Hodgkin lymphoma, or acute myeloid leukemia) are located in the body. It helps doctors understand how the agent spreads and how safe it is.
Hangzhou, ZhejiangAges 18–75 - NCT07290985RecruitingPhase 2
Can biomarkers guide organ-sparing treatment for stomach and esophagus cancer?
This trial tests if using specific biomarkers (like HER2 and PD-L1) can help choose the best treatment to potentially avoid surgery. It aims to preserve the stomach or esophagus while effectively treating the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06115772Recruiting
HPV and genital health in women with HPV-positive throat cancer
This study looks at HPV-related health in the genital and anal areas of women who have HPV-positive oropharyngeal cancer, or are the female partners of someone who does. The goal is to better understand how HPV affects these areas over time.
Rochester, MinnesotaAges 18 years+ - NCT07330037RecruitingPhase 2
TIL plus immunotherapy for NSCLC without complete response after chemoimmunotherapy
This trial tests a new treatment for people with non-small cell lung cancer (NSCLC) that was removed by surgery but did not completely disappear after pre-surgery chemoimmunotherapy. The treatment combines your own tumor-fighting cells (L-TIL, grown from your tumor) with an immunotherapy drug (tislelizumab) to try to keep the cancer from coming back.
Tianjin, Tianjin MunicipalityAges 17–75 - NCT05894694RecruitingPhase 4
Testing Compound Kushen injection for advanced colon cancer survival
This trial studies whether Compound Kushen injection can improve survival in people with advanced colorectal cancer. It’s aimed at people starting first-line treatment, and only includes certain cancer and health situations to keep results clear.
BeijingAges 18 years+ - NCT06463691RecruitingPhase 2
Sonrotoclax, Zanubrutinib, and CD20 Antibody for Untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs—sonrotoclax, zanubrutinib, and a CD20 antibody—as a first treatment for mantle cell lymphoma. It aims to see if this new combination is safe and effective for patients who have not yet received any treatment.
TianjinAges 18 years+ - NCT06490068RecruitingPhase 2
LTC004 with toripalimab for immunotherapy-resistant solid tumors
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
BeijingAges 18–75 - NCT07657494Recruiting
PET scan study for aggressive lymphoma patients
This study uses a special PET/CT scan to look at the environment around your lymphoma. The goal is to see if this scan can predict how well your treatment will work and your long-term outcome.
Beijing, Chao YangAges 18 years+ - NCT06521866RecruitingPhase 2
Study of serplulimab plus standard therapy for advanced colorectal cancer
This trial tests an immunotherapy drug (serplulimab) combined with targeted therapy, chemo, and radiation as a first treatment for people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if this combination can help control the cancer.
Fuzhou, FujianAges 18 years+ - NCT06320717Recruiting
AI-guided pre-surgery treatment for pancreatic cancer
This study tests how well an AI tool can guide which pre-surgery treatment is best for people with pancreatic cancer that can be removed. It uses your tumor's genetic fingerprint to choose the most effective therapy.
Buffalo, New YorkAges 18 years+ - NCT06108531Enrolling by invitation
Using tumor exosomes to diagnose pancreatic cancer
This study uses a simple blood test to detect tiny particles from tumors, called exosomes, to help diagnose pancreatic cancer or chronic pancreatitis. It aims to improve early detection and guide treatment decisions.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05177133RecruitingPhase 2
First-line treatment for MSI-high stomach or esophagus cancer
This Phase 2 trial tests whether adding an anti–PD-1 immunotherapy (retifanlimab) and chemotherapy (capecitabine plus oxaliplatin, with leucovorin) works better for people with metastatic or inoperable stomach or gastroesophageal junction cancer that has defective mismatch repair (dMMR). If you’re eligible, it may help shrink tumors and slow the disease without needing prior chemotherapy for metastatic cancer.
AmsterdamAges 18 years+ - NCT07392541RecruitingPhase 1/Phase 2
Study of adebrelimab plus chemo and simvastatin for bile duct cancer
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy (gemcitabine and cisplatin), and a cholesterol-lowering drug (simvastatin) for advanced bile duct or gallbladder cancer that cannot be removed by surgery. It aims to see if the addition of simvastatin improves treatment outcomes.
Wuhan, HubeiAges 18 years+ - NCT06487078Recruiting
Study of Lorlatinib for untreated ALK-positive lung cancer
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
Paris, ParisAges 18 years+ - NCT06095154RecruitingPhase 3
Simplifying radiation planning for nasopharyngeal cancer
This study tests a simpler way to plan radiation for a type of throat cancer called nasopharyngeal carcinoma. It uses a standard method to outline the area needing treatment, which may make planning faster and more consistent.
Fuzhou, FujianAges 18–70 - NCT07674732RecruitingPhase 2
Shorter radiation with immunotherapy for rectal cancer
This trial tests a shorter course of radiation followed by a combination of chemotherapy, immunotherapy, and a targeted drug (bevacizumab) for locally advanced rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink the tumor enough for surgery while avoiding more extensive radiation.
Guangzhou, GuangdongAges 18–75
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,626 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.